Alnylam Pharmaceuticals ALNY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.29B+82.6% | $3.71B+65.2% | $3.21B+53.2% | $2.46B+5.0% | $2.35B+17.2% | ||
| $814.5M+153% | $677.17M+121% | $512.09M+85.6% | $396.84M+45.2% | $322.08M+14.5% | ||
| $3.47B+71.4% | $3.04B+56.4% | $2.7B+48.3% | $2.07B-0.3% | $2.03B+17.7% | ||
| 81%-5.3pp | 81.8%-4.6pp | 84%-2.8pp | 83.9%-4.5pp | 86.3%+0.3pp | ||
| $1.42B+25.6% | $1.32B+17.2% | $1.25B+13.6% | $1.16B+7.3% | $1.13B+9.2% | ||
| $1.29B+28.7% | $1.21B+24.1% | $1.18B+34.4% | $1.08B+26.0% | $1B+22.1% | ||
| $3.53B+43.5% | $3.21B+32.5% | $2.95B+29.0% | $2.64B+17.9% | $2.46B+13.0% | ||
| $752.14M+752% | $501.58M+384% | $264.7M+241% | -$180.19M-276% | -$115.37M+34.4% | ||
| 17.5%+22.5pp | 13.5%+21.4pp | 8.2%+17.2pp | -7.3%-11.7pp | -4.9%+3.9pp | ||
| $219.33M+33.0% | $208.35M+46.9% | $181.92M+35.5% | $171.9M+31.5% | $164.91M+29.3% | ||
| $109.4M-9.6% | $111.47M-8.6% | $115.86M-4.5% | $119.32M+4.1% | $121.02M+13.6% | ||
| -$240.61M-19.8% | -$214.07M-6.8% | -$257.42M-93.6% | -$160.16M+2.5% | -$200.78M-34.8% | ||
| $511.53M+262% | $287.5M+176% | $7.29M+102% | -$340.35M-452% | -$316.16M+2.6% | ||
| —— | —— | -$75.51M-777% | -$60.49M-638% | -$85.68M-1,268% | ||
| $502.34M+318% | $278.1M+200% | $82.79M+125% | -$279.86M-284% | -$230.47M+30.6% | ||
| 11.7%+21.5pp | 7.5%+19.9pp | 2.6%+18.4pp | -11.4%-8.3pp | -9.8%+6.8pp | ||
| $3.66+304% | $2.01+193% | $0.54+121% | -$2.17-268% | -$1.79+33.0% | ||
| $3.79+312% | $2.10+197% | $0.61+123% | -$2.17-288% | -$1.79+32.2% | ||
| 540.9M+5.5% | 532.3M+4.6% | 525.3M+3.7% | 516.5M+1.5% | 512.7M+1.1% | ||
| 526M+2.6% | 522.8M+2.7% | 519.4M+2.6% | 516.5M+2.7% | 512.7M+2.3% | ||
| $7.45M+17.3% | $4.71M-72.1% | $4.87M-84.1% | $5.88M-81.3% | $6.35M-84.2% | ||
| $16.44M— | $10.9M— | $11.19M— | —— | —— | ||
| $514.96M+314% | $292.52M+201% | $85.84M+126% | -$275.18M-290% | -$241M+24.7% | ||
| -$2.53M+97.4% | -$2.2M+97.9% | -$82.42M-18,305% | -$88.18M-20,256% | -$97.58M-120,738% | ||
| $54.81M-4.8% | $55.66M-1.8% | $56.32M+0.6% | $56.5M+2.1% | $57.56M+7.6% | ||
| —— | —— | —— | —— | $15.34M+136% | ||
| —— | —— | $603.72M— | $240.95M— | $94.39M— | ||
| -$27.25M+88.4% | -$52.94M+77.5% | -$65.75M+67.9% | -$56.34M+68.2% | -$234.2M-763% | ||
| —— | —— | -$23.18M+6.3% | -$24.13M-2.3% | -$19.78M-5.3% | ||
| $98.06M+314% | $124.5M+3,956% | $28.23M— | $15.77M— | -$45.92M— | ||
| $213.98M+103% | $218.71M+224% | $117.72M+94.0% | $109.97M+103% | $105.56M+115% | ||
| —— | —— | -$319.51M-206% | $231.59M-0.5% | $311.33M+101% | ||
| $334.18M— | $473.5M— | $420.59M— | -$110.77M— | —— | ||
| $714.9M+1,618% | $524.08M+6,405% | $265.86M— | -$15.54M— | -$47.11M— | ||
| -$2.86M-162% | $1.82M+45,550% | -$2.97M-125% | $4.98M+7.7% | $4.59M+38.2% | ||
| -$8.28M+94.7% | $5.2M+103% | -$152.21M-26.7% | -$107.58M+27.4% | -$156.89M-22.6% | ||
| —— | —— | —— | -$58.56M-372% | -$51.83M-1,881% | ||
| $1.17B-27.9% | $1.31B-20.2% | $1.56B-10.4% | $1.78B+2.9% | $1.62B-10.6% | ||
| $71.56M+136% | $58.7M+71.2% | $44.5M+9.9% | $36.55M-31.5% | $30.27M-50.6% | ||
| $213.82M-34.5% | $250.03M-17.5% | $244.61M-17.8% | $274.9M+28.3% | $326.46M+149% | ||
| $4.29B+82.6% | $3.71B+65.2% | $3.21B+53.2% | $2.46B+5.0% | $2.35B+17.2% | ||
| $361.68M+27.6% | $348.24M+28.0% | $368.25M+65.6% | $305.84M+27.1% | $283.45M+24.8% | ||
| $752.14M+752% | $501.58M+384% | $264.7M+241% | -$180.19M-276% | -$115.37M+34.4% | ||
| $806.94M+1,496% | $557.24M+564% | $321.02M+343% | -$123.69M-178% | -$57.82M+52.7% | ||
| $806.94M+1,496% | $557.24M+564% | $321.02M+343% | -$123.69M-178% | -$57.82M+52.7% | ||
| 18.8%+21.3pp | 15%+20.4pp | 10%+16.3pp | -5%-11.8pp | -2.5%+3.6pp | ||
| $752.14M+752% | $501.58M+384% | $264.7M+241% | -$180.19M-276% | -$115.37M+34.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
